Tempus Labs (company)

Tempus Labs (company)

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

Tempus is an artificial intelligence company developing new treatment plans for patients with cancer by collecting molecular data. The information is then made available to physicians through an operating system that allows doctors to make data-driven treatment decisions with their patients. Tempus was founded by Eric Lefkosky, the co-founder of Groupon, in 2015.

Tempus uses genomic tests to analyze DNA, RNA, and proteomic data to understand a patient's tumor at the molecular level to identify treatment options that are patient-centric. The Tempus platform analyzes thousands of clinical and molecular data points, connecting physicians with up-to-date treatment options and insights for patients based on their molecular profile.

COVID-19 Response:

Tempus launched a diagnostic polymerase chain reaction (PCR) test for COVID-19. Tempus' CAP-accredited/CLIA-certified labs in Chicago and Atlanta are supporting the acceleration of testing in the U.S, and expect to test approximately 12,000 patients daily across both labs, with the ability to scale further if needed.

Tempus offers an on-demand virtual case review system that provides clinical support to physicians and care teams in a timely manner. Tempus' Medical Affairs team is available to answer patient report questions in real-time in a secure portal. In addition, Tempus now offers a variety of telehealth support services specific to COVID-19 if needed.

Tempus launched a large research collaboration to structure data for up to 50,000 COVID-19 positive patients. Tempus is partnering with providers to collect data on COVID-19 patients, which Tempus is structuring and de-identifying without cost. In addition, Tempus expects to perform full transcriptomic profiling of approximately 10,000 patients within the cohort. All data will be shared with all participating institutions without restriction.


December 11, 2019

Tempus acquired AKESOgen on Dec 11, 2019.

May 2019

Tempus Labs raises a $200,000,000 series F round from New Enterprise Associates, Novo Holdings A/S, Franklin Templeton Investments, Baillie Gifford and Revolution.

August 2018

Tempus Labs raises a $110,000,000 series E round from Revolution Growth, New Enterprise Associates, Baillie Gifford, Revolution and T. Rowe Price.

March 2018

Tempus Labs raises a $80,000,000 series D round from Revolution Growth, Revolution, T. Rowe Price and New Enterprise Associates.

September 2017

Tempus Labs raises a $70,000,000 series C round from Revolution Growth and New Enterprise Associates.

April 2017

Tempus Labs raises a $30,000,000 series B round.

November 2016

Tempus Labs raises a $10,000,000 series B round.

June 2016

Tempus Labs raises a $10,000,000 series B round.

September 2015

Tempus Labs raises a $10,000,000 series A round.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
8 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine



Colette Freeman

Chief of People Officer

Eric Lefkofsky

Founder & CEO

Erik Phelps

Chief Administrative and Legal officer

Kim Blackwell

Chief Medical Officer

Ryan Fukushima

Chief of Operations Officer

Shane Colley

Chief Technical Officer

Vanessa Rollings

Chief Financial Officer

Further reading


Chicago precision medicine startup Tempus nabs $200M for expansion - MedCity News

Erin Dietsche


May 30, 2019

Chicago's Tempus Labs Signs 5 Year Lease in Manhattan | CoStar

Natalie Silady


June 15, 2020

Following $110M fundraise, Tempus reveals mobile app to give doctors access to clinical data - MedCity News

Erin Dietsche


September 19, 2018

Health Data Startup Tempus Accused of Poaching Top Executive

Mike Leonard


December 4, 2019

Lefkofsky's Tempus raises $100 million to expand beyond cancer

John Pletz


March 13, 2020

Tempus Acquires Commercial Lab, Precision Medicine Services Provider Akesogen


December 13, 2019

Tempus closed $200 million funding round to reach $3 billion valuation - Business Insider

Zoë LaRock


May 31, 2019

Tempus: Health start-up backed by Groupon co-founder joins the fight against Covid-19

Daniel Bukszpan


June 17, 2020

Documentaries, videos and podcasts





May 30, 2020
Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, introduced a series of offerings designed to both advance vital research and support physicians in treating cancer patients, despite the challenges of the COVID-19 pandemic.
Business Standard Editorial Comment
May 14, 2020
MPC will have to work with an incomplete inflation picture
Connie Loizos
May 31, 2019
When serial entrepreneur Eric Lefkofsky grows a company, he puts the pedal to the metal. When in 2011 his last company, the Chicago-based coupons site Groupon, raised $950 million from investors, it was the largest amount raised by a startup ever. It was just over three years old at the time, and it went public [...]


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.